Ketamine in the Treatment of Major Depressive Disorder

被引：3
|
作者：
Luu, Brent [1 ]
Rice, Elizabeth [1 ]
Goldin, Philippe [1 ]
机构：
[1] Univ Calif Davis, Betty Irene Moore Sch Nursing, Sacramento, CA 95817 USA
来源：
JNP-JOURNAL FOR NURSE PRACTITIONERS | 2020年 / 16卷 / 03期
关键词：
depression; ketamine; major depressive disorder (MDD); mechanism of ketamine; psychiatric conditions; treatment of MDD; GAMMA-AMINOBUTYRIC-ACID; COMPLICATIONS; PHARMACOLOGY; INFUSIONS; GLUTAMATE; CARE;
D O I：
10.1016/j.nurpra.2019.07.016
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Major depressive disorder (MDD) is a prevalent and highly debilitating psychiatric condition that affects many young adults worldwide. This brief review summarizes the current available data about the use of ketamine as a treatment for MDD. We describe pharmacological mechanisms, dose considerations, drug interactions, side effects, and the relevancy of ketamine in the treatment of MDD. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码：228 / 231
页数：4
相关论文
共 50 条
  • [21] Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies
    Crisanti, Camilla
    Enrico, Paolo
    Fiorentini, Alessio
    Delvecchio, Giuseppe
    Brambilla, Paolo
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2020, 276 : 1109 - 1118
  • [22] Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder
    Aust, Sabine
    Gaertner, Matti
    Basso, Laura
    Otte, Christian
    Wingenfeld, Katja
    Chae, Woo Ri
    Heuser-Collier, Isabella
    Regen, Francesca
    Cosma, Nicoleta Carmen
    van Hall, Franziska
    Grimm, Simone
    Bajbouj, Malek
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 (04) : 529 - 538
  • [23] The quest for optimal ketamine dosing formula in treatment-resistant major depressive disorder
    Kwasna, Julia
    Cubala, Wieslaw Jerzy
    Kwasny, Aleksander
    Wilkowska, Alina
    [J]. PHARMACOLOGICAL REPORTS, 2024,
  • [24] A CASE OF SUCCESSFUL KETAMINE TREATMENT AFTER ECT FAILURE IN A PATIENT WITH MAJOR DEPRESSIVE DISORDER
    Chatham, Anthony
    Deppe, John
    Subler, Ashley
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2021, 29 (04): : S25 - S25
  • [25] Treatment for major depressive disorder
    Zhang, X.
    [J]. PSYCHOTHERAPY AND PSYCHOSOMATICS, 2015, 84 : 81 - 81
  • [26] Modulation of the functional connectome in major depressive disorder by ketamine therapy
    Sahib, Ashish K.
    Loureiro, Joana R.
    Vasavada, Megha
    Anderson, Cole
    Kubicki, Antoni
    Wade, Benjamin
    Joshi, Shantanu H.
    Woods, Roger P.
    Congdon, Eliza
    Espinoza, Randall
    Narr, Katherine L.
    [J]. PSYCHOLOGICAL MEDICINE, 2022, 52 (13) : 2596 - 2605
  • [27] Efficacy of different doses of ketamine as a bolus in major depressive disorder
    Kheirkhah, Farzan
    Tayyebi, Gooya
    Rabiee, Seyed Mozaffar
    Moghadamnia, Ali-Akbar
    Bijani, Ali
    [J]. CASPIAN JOURNAL OF INTERNAL MEDICINE, 2018, 9 (03) : 220 - 227
  • [28] A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
    Lapidus, Kyle A. B.
    Levitch, Cara F.
    Perez, Andrew M.
    Brallier, Jess W.
    Parides, Michael K.
    Soleimani, Laili
    Feder, Adriana
    Iosifescu, Dan V.
    Charney, Dennis S.
    Murrough, James W.
    [J]. BIOLOGICAL PSYCHIATRY, 2014, 76 (12) : 970 - 976
  • [29] Intravenous Ketamine for Treatment of Major Depressive Disorder in a Patient with a History of Repetitive Traumatic Brain Injuries
    Dougherty, John, III
    [J]. BRAIN INJURY, 2019, 33 : 211 - 212
  • [30] The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review
    Boudieu, Ludivine
    Mennetrier, Myriam
    Llorca, Pierre-Michel
    Samalin, Ludovic
    [J]. PHARMACEUTICS, 2023, 15 (12)
12345